Anika Therapeutics Inc. Free Cash Flow

Free Cash Flow of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.

Highlights and Quick Summary

  • Free Cash Flow for the quarter ending September 29, 2021 was $1.18 Million (a -51.86% decrease compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow decreased by -48.67%
  • Annual Free Cash Flow for 2020 was $12.9 Million (a -63.47% decrease from previous year)
  • Annual Free Cash Flow for 2019 was $35.2 Million (a 16.46% increase from previous year)
  • Annual Free Cash Flow for 2018 was $30.3 Million (a -4.93% decrease from previous year)
  • Twelve month Free Cash Flow ending September 29, 2021 was $3.45 Million (a -59.33% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow decreased by -71.75% year-over-year
Trailing Free Cash Flow for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$3.45 Million $8.48 Million $9.42 Million $12.2 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of Anika Therapeutics Inc.

Most recent Free Cash Flowof ANIK including historical data for past 10 years.

Interactive Chart of Free Cash Flow of Anika Therapeutics Inc.

Anika Therapeutics Inc. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1.18 $2.44 $-2.46
2020 $2.29 $6.21 $3.38 $0.32 $12.88
2019 $12.75 $9.62 $4.37 $7.43 $35.24
2018 $9.85 $9.63 $3.73 $7.05 $30.26
2017 $4.51 $9.51 $4.03 $13.79 $31.83
2016 $4.66 $8.58 $-4.43 $1.63 $9.79
2015 $8.92 $8.01 $10.02 $3.73 $30.69
2014 $14.12 $7.14 $3.84 $13.32 $38.43
2013 $7.46 $7.68 $3.6 $6.17 $24.91
2012 $4.6 $2.05 $4.3 $-1.91 $9.04
2011 $6.86 $2.68 $-1.98 $1.21 $8.77

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.